Cytokinetics says Phase 3 ACACIA — HCM data show aficamten boosts exercise performance in non — obstructive HCM

Additional ACACIA-HCM trial analyses were presented at the HFSA Annual Scientific Meeting 2026, extending evidence for aficamten in non-obstructive HCM. New exercise-performance analyses showed broader improvement versus placebo, aligning with better patient-reported health status and supportive biomarker trends. A responder analysis indicated more patients on aficamten achieved meaningful overall clinical benefit across multiple domains than placebo. Safety updates highlighted heart-failure events concentrated during early dose titration, supporting a titration approach guided by heart-pumping function monitoring. Cytokinetics plans to file a supplemental New Drug Application with the FDA this quarter to expand aficamten’s label into non-obstructive HCM. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via (Ref. ID: 202610121600PRIMZONEF